v3.20.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Cash Flows From Operating Activities    
Net loss $ (26,727) $ (12,189)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 4,187 3,464
Interest accretion 440 331
Bad debt expense 499
Reversal of DOJ accrual (350)
Mark to market on warrants (279) 112
Stock-based compensation 1,535 2,270
Deferred income taxes 18
Change in estimate on collectability of accounts receivable 3,479
Change in fair value of contingent consideration (44) 1,522
Other gains and expenses, net 18
Other changes in operating assets and liabilities:    
Increase in accounts receivable (961) (3,546)
Decrease (increase) in other current assets 129 (501)
Increase in other long-term assets (11)
(Decrease) increase in accounts payable (835) 668
Increase in accrued salaries and bonus 482 30
Decrease in accrued liabilities (1,341) (402)
Increase (decrease) in long-term liabilities 454 (82)
Net cash used in operating activities (18,957) (8,673)
Cash Flows From Investing Activity    
Acquisition of Biopharma, net of cash acquired (13,829)
Purchase of property and equipment (131) (449)
Sale of property and equipment 13
Net cash used in investing activity (13,947) (449)
Cash Flows From Financing Activities    
Issuance of common stock, net of expenses 6,478
Issuance of preferred stock, net of expenses 25,744
Payment of Seller's note (6,024)
Borrowings on Line of Credit 3,000
Cash paid for repurchase of restricted shares (41) (9)
Net cash provided by (used in) financing activities 29,157 (9)
Net decrease in cash and cash equivalents (3,747) (9,131)
Cash and cash equivalents - beginning of year 6,068 15,199
Cash and cash equivalents - end of year $ 2,321 $ 6,068

Source